Slide 1: Sinovac Biotech Ltd. May 2011
Sinovac Biotech Ltd. May 2011
Slide 2: Disclaimer
Disclaimer This presentation does not constitute an offer to sell or issue, or the solicitation of an offer to buy or acquire securities of Sinovac Biotech Ltd. (the “Company”) in any jurisdiction, or an inducement to enter into investment activity, nor may it or any part of it form the basis of or
Slide 3: Company Overview and Key Milestones
Company Overview Key Milestones NASDAQ GSM Listed Company (Ticker: SVA) • Filed IND for PCV, PPV and Rubella Founded in 2001, headquartered in Beijing 2011 • Completed EV71 phase I clinical trial in Fully integrated China-based biopharmaceutical adult group company focused on researching, developing
Slide 4: Our Mission
Our Mission Supply Vaccines To Eliminate Human Diseases • Provide Chinese Children with International Quality Vaccines • Provide Children in the World with Vaccines Made in China 4
Slide 5: Sinovac Organizational Structure
Sinovac Organizational Structure Retail Investors: 62.8% Insiders 11%1 Institutional Investors: Retail Investors: Dr. Weidong Yin (Chairman): 11%1 45.6%1 43.4%1 NASDAQ GSM:SVA Sinovac Biotech Ltd. Registered in Antigua and Barbuda 100% Sinovac Biotech（Hong Kong) Ltd. SinoBioWay Jin Gang Group
Slide 6: Development of China Vaccine Quality Management System
Development of China Vaccine Quality Management System China SFDA complies with international standards for vaccine New Version of China regulation GMP Standards New version of Chinese Pharmacopeia • February 2011 • February 2011 • October 2010 Chinese vaccine manufacturers facing higher level of pr
Slide 7: Focus on Five Key Strategic Objectives
Focus on Five Key Strategic Objectives Develop new products to serve unmet medical needs Expand production capacity to serve growing demand from China and other developing markets Sinovac aims to: Develop more vaccines against more types of disease Maintain the high quality to comply with internatio
Slide 8: Current Product Portfolio
Current Product Portfolio Healive (Hep A) Vaccine Bilive (Hep A & B) Vaccine 1st inactivated Hepatitis A vaccine developed, Largest combined inactivated hepatitis A and B produced, and marketed by a Chinese manufacturer vaccine supplier in China License granted in Nepal; Registration commenced in Ma
Slide 9: Deep Pipeline to Drive Future Growth
Deep Pipeline to Drive Future Growth Pre- File Clinical Trials Clinical Trials Pipeline Clinical Reg. Market Potential IND P1 P2 P3 Human Vaccines 1.79 million cases reported in China with 888 • EV71 Vaccine (hand, foot fatalities in 2010, compared with 1.15 million and mouth disease) reported cas
Slide 10: EV71 Vaccine - Phase I Clinical Trial Updates
EV71 Vaccine- Phase I Clinical Trial Updates Design • Single center, randomization, double blinded, and placebo controlled Purposes • Evaluate safety, tolerance profile and preliminary immunogenicity Protocol • Adult group first and followed by the young children group and the infant group • Startin
Slide 11: Well-Established Sales, Marketing and Distribution Network
Well-Established Sales, Marketing and Distribution Network Sell products directly to CDCs, which enables enhanced supply chain control and deeper understanding of end market Expertise not only on pediatric market, but also adult market Maintaining leading position not only in top tier cities, but al
Slide 12: Advanced Manufacturing Facilities with Stringent Quality Assurance
Advanced Manufacturing Facilities with Stringent Quality Assurance Dalian: Vero Cell Cultured Vaccine Beijing and Live Attenuated Vaccine Headquarters (95,000 square meters) Dalian Beijing Tangshan Changping District, Beijing Vaccine Production Center Tangshan Yian Animal Vaccine (29,000 square mete
Slide 13: Experienced and Committed Management Team
Experienced and Committed Management Team Over 60 years of combined vaccine industry experience Management Highlights: Proven entrepreneurial success Expertise in operating high growth company Strong capability to develop and commercialize vaccines High standards of corporate governance R&
Slide 14: Financial Performance
Financial Performance Revenue Gross Profit and Margin1 $90 $84 $70 90% 64.13 $80 $60 80% $70 81% 76% 79% (US$m) $50 (US$m) $60 72% 70% $46 $40 36.56 $50 60% $40 $30 27.04 $34 $33 49.9% $30 16.68 50% $20 $15 11.12 $20 40% $10 $10 $0 30% $0 2006 2007 2008 2009 2010 2006 2007 2008 2009 2010 Operating I
Slide 15: New Sales Strategy
New Sales Strategy Public Market (EPI) Hepatitis A Vaccine AR Management Special Task • Evaluating market & Monitoring Force opportunities • Implementing strategy to gain market share Clinical Study Support Sales Strategy Adjustments Better Intensive Policy Private Market Hepatitis A Vaccine Trainin
Slide 16: Key Financial Results in 2011 Q1
Key Financial Results in 2011 Q1 Total Revenue Regular Sales Revenue (Non-H1N1) ( in thousand US) (in thousand US) $5,000 $4,681 EPI Private Market 5.3% $4,500 $5,000 Text $5,000 $4,681 50.4% Text $4,444 $3,733 $4,500 $4,000 $4,500 $4,000 $3,500 $4,000 $3,112 32% $3,500 $3,500 $3,000 $2,831 $3,000 $
Slide 17: Thank you!
Thank you! — we sinovac .